Kuehn Law, PLLC is investigating whether certain officers and directors of Arcus Biosciences, Inc. breached their fiduciary duties through potential self-dealing. The investigation could lead to shareholder damages and corporate governance reforms. Long-term shareholders are encouraged to contact the law firm for a free consultation, as there may be limited time to enforce their rights. This legal action highlights concerns about management accountability and shareholder protection at Arcus Biosciences.
Remittix has raised $33 million in its presale, nearing its $36 million hard cap ahead of its November 24, 2026 launch. The project offers a PayFi ecosystem connecting crypto with bank payments, with active product use and testing underway. Meanwhile...
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Ora Banda Mining has advanced its Davyhurst Gold Project in Western Australia by starting underground development at Waihi ahead of schedule and progressing construction of a new 3 million tonnes per annum processing plant on time and within budget. ...
